Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH-OUTCOMES retatrutide cardiovascular and kidney outcomes study
NL-OMON60031Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3 trial of retatrutide in obesity and Overweight, sponsored by Eli Lilly and Company. Primary endpoints: Time to first occurrence of major cardiovascular composite endpoint and Time to first occurrence of kidney composite endpoint. Started May 2024; status: active, not recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON60031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60031.